뉴스벤징가
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
· 발표
기사 요약
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
기사 원문에서 발췌했어요.뉴스 본문을 불러오고 있어요.
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…